Navigation Links
Neurocrine Biosciences to Present at the Bear Stearns Healthcare Conference
Date:9/10/2007

Live Audio Webcast Tuesday, September 11, 2007

SAN DIEGO, Sept. 10 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Neurocrine Biosciences will present at the Bear Stearns Healthcare Conference. The live presentation takes place Tuesday, September 11, 2007 at 10:30 a.m. Eastern Time (ET) /7:30 a.m. Pacific Time (PT). The presentation will be simultaneously webcast and may be accessed on the Company's website at http://www.neurocrine.com

If you are unable to attend the webcast and would like further information on this announcement please contact the Investor Relations Department at Neurocrine Biosciences at (858) 617-7600. Viewers are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software. A replay of the presentation will be archived on the website for two weeks.

About Neurocrine

Neurocrine Biosciences, Inc. is a product-based biopharmaceutical Company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including insomnia, anxiety, depression, endometriosis, pain, irritable bowel syndrome, and autoimmunity. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the Internet at http://www.neurocrine.com.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Quintessence Biosciences names new president
5. Caden Biosciences may signal critical mass
6. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
7. WARF signs licensing pact with BD Biosciences
8. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
9. State awards QRG Biosciences development grant
10. EMD Biosciences partners with European biotech company
11. Quintessence Biosciences forms cancer therapeutic advisory board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014 The largest international professional organization of ... therapeutic derivatives thereof has endorsed an educational program ... the challenges of adulterated herb and botanical products. ... The Society for Medicinal Plant and Natural ...
(Date:1/14/2014)... 2014 iLab Solutions, the leader in core ... Director of Product Strategy. In this role, Michelle will work ... to guide in the development of iLab products. Her main ... possible benefit to the scientific community by offering the most ...
(Date:1/14/2014)...  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company ... addressing major unmet medical needs using RNA-targeted technologies, ... Allowance from the United States Patent and Trademark ... for the treatment of fibrosis. The patent covers ...
(Date:1/14/2014)... Ontario , Jan. 14, 2014   Kinaxis ®, provider ... SCM ) and sales and operations planning ( S&OP ) ... Biomanufacturing Summit , which will be held at the ... the conference, join Kinaxis customer Elisabeth Kaszas , Director ...
Breaking Biology Technology:World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... March 25 Trubion Pharmaceuticals, Inc. (Nasdaq: ... Pharmaceuticals, a division of Wyeth (NYSE: WYE ... SBI-087, Trubion,s next generation CD20 drug candidate, for the ... Small Modular ImmunoPharmaceutical (SMIP(TM)) technology, SBI-087 is also being ...
... PHILADELPHIA, March 25 In an economic environment ... Prime Health Network and its patients are thriving ... industry leading healthcare payments network and platform, Prime ... their costs related to collections, while also improving ...
... a privately held biotechnology company focused on developing novel ... sindbis viral vector, today announced that Frank Stonebanks, President ... National Venture Conference in Boston on Wednesday, April 1, ... LLC , Cynvec, a privately held biotechnology company, ...
Cached Biology Technology:Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE) 2Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE) 3Prime Health Network and Its Patients Thrive in Tough Economic Times on the InstaMed Network 2Prime Health Network and Its Patients Thrive in Tough Economic Times on the InstaMed Network 3
(Date:4/17/2014)... one per eight hundred births, Down syndrome - or ... of intellectual disability. It results from a chromosomal abnormality ... of chromosome 21 (1% of the human genome). A ... the Department of Genetic Medicine and Development at the ... Nature , shed light on how the extra ...
(Date:4/17/2014)... House honored Clemson professor Rajendra Singh Thursday as ... promote and expand solar deployment in the residential, ... Houser Banks Professor of Electrical and Computer Engineering ... is considered a local hero leading the charge ... opportunity in solar power and driving policy changes ...
(Date:4/17/2014)... are implicated in many serious conditions such as heart ... target for drug therapies. Unfortunately, there is still much ... research provides fresh and unexpected insight into the structure ... - β-subunit molecules - which are responsible for ,fine-tuning, ... in the most recent edition of the Journal ...
Breaking Biology News(10 mins):Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3White House honors Clemson professor as 'Champion of Change' for solar deployment 2Structure of sodium channels different than previously believed 2
... Researchers at Northwestern University have developed a new ... providing an alternative that is more flexible and ... describing the results, "Low-Pressure Foaming: A Novel Method ... Engineering," was featured in the February issue of ...
... and Shenzhen, China BGI, the world,s largest ... Research Center located in Copenhagen Bio Science Park ... meters and equipped with 10 Illumina HiSeq 2000 ... better accelerate the innovation and development of genomics ...
... ON., Feb. 10, 2012--St. Michael,s Hospital and King Saud University ... BRCA1 gene as a therapy for cardiovascular disease. Dr. ... Mohammed Al-Omran, a vascular surgeon at the largest university in ... 110,185 B2 issued Feb. 7. Obtaining the patent is ...
Cached Biology News:Researchers develop new method for creating tissue engineering scaffolds 2BGI opens genome research center in Europe 2BGI opens genome research center in Europe 3
...
... with Annexin V-FITC to distinguish cells that ... (Annexin V positive, PI negative) from those ... or already dead (Annexin V-FITC positive, PI ... range of the spectrum using a 562-588 ...
... RPMI 1640 with 2 mM L-glutamine and harvested ... order to keep the antigens in their native ... cells are arrayed on a 12-well (5 mm) ... treated to enhance cellular attachment and to minimize ...
... is a software package that provides ... for custom buffer creation, set-up of ... crystallization trials. The software helps crystallographers ... automated protein crystallography: ...
Biology Products: